Elizabeth Mily

Chair

---

Elizabeth A. Mily, CEO of the T1D Fund, is a healthcare and financial industry veteran with 30+ years of experience across biopharma, life sciences, and global healthcare investing. Most recently, she served as Executive Vice President, Strategy & Business Development at Bristol Myers Squibb, and before that spent 26 years on Wall Street at Barclays and Goldman Sachs. She was also a senior executive at Thermo Fisher Scientific. Outside of the T1D Fund, she currently serves on the Board of Directors of Solventum Corporation (NYSE: SOLV) and is a director of Ampersand Biomedicines. She is passionate about advancing T1D innovation for all patients, motivated by both her husband and father-in law who are T1D patients. Elizabeth holds an M.S. in Foreign Service from Georgetown University and a B.A. from The Ohio State University. She chairs the T1D Fund’s Investment Committee and serves on the Nominating & Governance, Capital, and Compensation Committees.